LAS VEGAS--(BUSINESS WIRE)--Optovue, the global leader in the development of optical coherence tomography (OCT) and OCT angiography (OCTA), will showcase AngioAnalytics™, the world’s first OCTA blood vessel measurement technology to help clinicians manage diseases that cause progressive blindness, and 3D PAR, its three-dimensional projection artifact removal software at Vision Expo West 2018. The company will also highlight its 9mm Epithelial Thickness Mapping (ETM), a wider version of its non-contact, quantitative method for corneal epithelia and stromal measurements, and debut its new non-mydriatic ophthalmic camera, Vivicon, offering a touch-screen tablet interface with fully automatic alignment and image capture.
Optovue recently received FDA 510(k) clearance for AngioAnalytics, and expanded FDA clearance for ETM, which added the nine-millimeter ETM scan to the previously available six-millimeter map, allowing for detection of epithelial irregularities in an area that is about two-and-a-quarter times that of the area covered by the six-millimeter scan.
“Optovue continues to advance the eye care industry with software such as AngioAnalytics,” said Julie Rodman, O.D., M.S., FAAO, associate professor at Nova Southeastern University College of Optometry. “This technology allows for an objective assessment of the microvasculature, which ultimately results in more timely detection of disease and optimizes patient management.”
AngioAnalytics brings objective data and analysis to Optovue’s commercially available AngioVue® OCTA technology that provides high-resolution imaging of retinal blood vessels. Combined, the two technologies create color-encoded maps of the vessel densities of the retina or optic nerve, and provide analyses of areas where there is blood vessel loss (non-perfusion), abnormal blood vessel growth (flow area), and several parameters to assess change to the foveal avascular zone, an area of the retina profoundly affected by diabetic retinopathy. The AngioAnalytics software also provides trend analysis so that doctors can objectively monitor retinal and vascular changes caused by disease progression or from treatment.
Optovue’s ETM, now available on the Avanti® Widefield OCT system, is the first and only FDA-cleared OCT product indicated to provide corneal epithelial and stromal measurements that aid in the diagnosis, documentation and management of ocular health and diseases in the adult population. The measurement of corneal epithelial thickness is recognized by eye care professionals as a vital part of assessing patients for refractive surgery and following post-operative recovery, as well as managing patients with progressive eye diseases and ocular surface disorders.
“With epithelial thickness mapping, we are able to better diagnose, monitor and treat our patients with keratoconus, dry eye, and fluctuating vision following refractive or other anterior segment surgeries,” said S. Barry Eiden, O.D., FAAO, FSLS, president and medical director of North Suburban Vision Consultants, Ltd. “We have integrated ETM into our patient consultation workflow and we are able to educate and update our patients about their conditions very easily while also adjusting any management protocols to optimize outcomes.”
Expanding its product offering for eye care providers, Optovue’s Vivicon ophthalmic camera is an easy-to-use, non-mydriatic fundus camera that includes fully automatic 3D tracking and image capture, making the operation simple for technicians and comfortable for patients. Retinal and external images can be reviewed on the touch-screen tablet or exported to an exam lane or office network. The affordable Vivicon camera is commercially available in the U.S.
“We are excited to introduce our new Vivicon ophthalmic camera at the Vision Expo West, as it is a great venue conducive to meeting and interacting with eye care professionals and showcasing new products,” said Jay Wei, founder and chief executive officer of Optovue. “We are also pleased to highlight AngioAnalytics technology as part of the AngioVue System to aid physicians in the early detection and management of sight-threatening eye diseases in the U.S. The information provided by AngioAnalytics may help to change the clinical management of diabetic retinopathy, age-related macular degeneration and other diseases that progressively cause blindness for millions of people.
“With our ETM software, we are already witnessing a change in the way physicians assess the cornea and we believe ETM will become an essential part of anterior segment eye exams in daily clinical practice,” continued Wei.
Optovue will debut the new Vivicon ophthalmic camera and also highlight AngioAnalytics and ETM in booth # MS5035 at the Sands Expo & Convention Center, Sept. 26-29, 2018.
About Optovue
Optovue, Inc. is a privately held medical device company founded in 2003. Headquartered in Fremont, Calif., the company is dedicated to the advancement and commercialization of high-speed OCT and OCTA technology used to facilitate the diagnosis and management of eye diseases, many of which may lead to permanent blindness. Optovue is the first company to develop and commercialize the pioneering OCTA technology. To date, there are over 400 peer-reviewed publications detailing the AngioVue® OCTA imaging technology and clinical applications. The company has installed over 12,000 products worldwide. For more information, visit www.optovue.com.
